> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Maintaining User Fee Activities
- URL: https://www.fdaweb.com/fda-maintaining-user-fee-activities/
- Published: 2020-04-16T12:00:00.000Z
- Updated: 2026-09-14T16:11:36.000Z
- Author: David McFarland
- Tags: Drugs, Devices, #legacy-id-D5146582

FDA commissioner **Stephen Hahn** says that to date the agency staff has been performing user fee review activities despite also being heavily involved in Covid-19-related activities. In a [statement](https://www.prnewswire.com/news-releases/coronavirus-covid-19-update-fda-continues-user-fee-related-reviews-through-covid-19-301042198.html?ref=fdaweb.com), Hahn says that part of the review activities has involved looking at ways to use technology and established agreements with foreign counterparts to minimize the impact to applications under review.

He cautions that with so many CBER, CDER, and CDRH staff working on Covid-19-related activities, the agency might not be able to sustain its current performance level indefinitely.

“It is difficult to speculate on what the exact impact will be on incoming submissions moving forward,” Hahn concludes. “We are seeing and hearing from industry that companies are taking a role as partners in the defense of public health by prioritizing their work and submissions. As this remains an evolving and very dynamic situation, FDA will continue to be flexible and as transparent as possible as we work to address the Covid-19 pandemic, as well as keep other key mission-critical initiatives unrelated to the pandemic moving forward.”